In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cancer Genetics Inc.

www.cancergenetics.com

Latest From Cancer Genetics Inc.

Appointments: Stada, Astellas, Novo Nordisk, Boehringer Ingelheim, Dova, Selvita, Orchard, MannKind, Cancer Genetics

The latest biopharma industry appointments include CEOs for Stada and Astellas, a finance chief for Novo Nordisk and a new president for Boehringer Ingelheim in the US, while Orchard Therapeutics has made a key addition to its scientific advisory board.

Appointments BioPharmaceutical

Deals Shaping the Medical Industry, January 2018

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2017.

Deals BioPharmaceutical

Biopharma Quarterly Dealmaking Statistics, Q3 2017

Third-quarter biopharma financing, which totaled $12.5 billion, was dominated by follow-on public offerings, which represented virtually half the value. Acquisition activity was headlined by a major move by Gilead in the CART market. Five alliances were signed worth over $1 billion, led by a partnership between two key players, Merck & Co. and AstraZeneca.

BioPharmaceutical Deals

Deals Shaping The Medical Industry, September 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in August 2017.

Deals Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
    • Molecular Diagnostics & Genetic Testing
  • Laboratory Testing Services
    • Esoteric Laboratories
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Cancer Genetics Inc.
  • Senior Management
  • John A Roberts, Pres. & CEO
    Glenn Miles, CFO
    Michael McCartney, Chief Commercial Officer
  • Contact Info
  • Cancer Genetics Inc.
    Phone: (201) 528-9200
    201 Rte. 17 North
    2nd Fl.
    Rutherford, NJ 07070
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register